StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$957.76+5.36 (+0.56%)

Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –

Regeneron Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Regeneron Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $16.90B, up 18.6% year over year. For fiscal 2025 it was $14.34B, up 1.0% from the year before. Over ten years it grew 13.3% a year on average. The highest annual figure on record is $16.07B in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.34B+1.0%
FY2024Dec 31, 2024$14.20B+8.3%
FY2023Dec 31, 2023$13.12B+7.8%
FY2022Dec 31, 2022$12.17B-24.3%
FY2021Dec 31, 2021$16.07B+89.1%
FY2020Dec 31, 2020$8.50B+29.6%
FY2019Dec 31, 2019$6.56B+27.4%
FY2018Dec 31, 2018$5.15B-12.4%
FY2017Dec 31, 2017$5.87B+20.8%
FY2016Dec 31, 2016$4.86B+18.4%
FY2015Dec 31, 2015$4.10B+45.5%
FY2014Dec 31, 2014$2.82B+34.0%
FY2013Dec 31, 2013$2.10B+52.7%
FY2012Dec 31, 2012$1.38B+209.2%
FY2011Dec 31, 2011$445.82M-2.9%
FY2010Dec 31, 2010$459.07M+21.0%
FY2009Dec 31, 2009$379.27M+59.1%
FY2008Dec 31, 2008$238.46M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$5.12B+36.3%
Q2 FY2026Jun 30, 2026$4.29B+16.7%
Q1 FY2026Mar 31, 2026$3.61B+19.0%
Q4 FY2025Dec 31, 2025$3.88B+2.5%
Q3 FY2025Sep 30, 2025$3.75B+0.9%
Q2 FY2025Jun 30, 2025$3.68B+3.6%
Q1 FY2025Mar 31, 2025$3.03B-3.7%
Q4 FY2024Dec 31, 2024$3.79B+10.3%
Q3 FY2024Sep 30, 2024$3.72B+10.6%
Q2 FY2024Jun 30, 2024$3.55B+12.3%
Q1 FY2024Mar 31, 2024$3.15B-0.5%
Q4 FY2023Dec 31, 2023$3.43B+0.6%
Q3 FY2023Sep 30, 2023$3.36B+14.5%
Q2 FY2023Jun 30, 2023$3.16B+10.5%
Q1 FY2023Mar 31, 2023$3.16B+6.6%
Q4 FY2022Dec 31, 2022$3.41B-31.0%
Q3 FY2022Sep 30, 2022$2.94B-15.0%
Q2 FY2022Jun 30, 2022$2.86B-44.4%
Q1 FY2022Mar 31, 2022$2.97B+17.3%
Q4 FY2021Dec 31, 2021$4.95B+104.4%
Q3 FY2021Sep 30, 2021$3.45B+50.5%
Q2 FY2021Jun 30, 2021$5.14B+163.2%
Q1 FY2021Mar 31, 2021$2.53B+38.3%
Q4 FY2020Dec 31, 2020$2.42B+30.0%
Q3 FY2020Sep 30, 2020$2.29B+31.6%
Q2 FY2020Jun 30, 2020$1.95B+23.7%
Q1 FY2020Mar 31, 2020$1.83B+33.2%
Q4 FY2019Dec 31, 2019$1.86B-3.3%
Q3 FY2019Sep 30, 2019$1.74B+4.8%
Q2 FY2019Jun 30, 2019$1.58B-1.9%
Q1 FY2019Mar 31, 2019$1.37B-9.2%
Q4 FY2018Dec 31, 2018$1.93B+21.8%
Q3 FY2018Sep 30, 2018$1.66B+10.8%
Q2 FY2018Jun 30, 2018$1.61B+9.4%
Q1 FY2018Mar 31, 2018$1.51B+14.6%
Q4 FY2017Dec 31, 2017$1.58B+29.0%
Q3 FY2017Sep 30, 2017$1.50B–
Q2 FY2017Jun 30, 2017$1.47B–
Q1 FY2017Mar 31, 2017$1.32B–
Q4 FY2016Dec 31, 2016$1.23B–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?